{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 49,
  "pageCount": 56,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes RECIST 1.1 criteria reference and patient progression note.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/49",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.77,
        "y": 0.65
      },
      "kind": "callout",
      "text": "31% reduction in tumor size",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afc20e13-2784-4f7a-b471-dbdb99f0c573",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.5,
        "x": 0.22,
        "y": 0.45
      },
      "kind": "image",
      "text": "Baseline vs 16 Weeks CT scans",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ab2da64-28de-4777-8bcd-d09676f71149",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Per RECIST 1.1: ≥30% = objective response",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5036a394-b7bd-4531-9126-d2a0bcae6e22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.5,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Patient progressed with new lesion at subsequent assessment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edc1f508-02d9-4f2c-8a7e-ce47b446ecee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.95,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "table",
      "text": "Diagnosis: Stage II pancreatic cancer, metastatic disease, KRAS G12V, initially diagnosed in January 2018. Sites of Metastases: Lung, lymph nodes. Prior Therapy: Surgery, adjuvant radiation, gemcitabine/ capecitabine (#1); 5FU/oxaliplatin/irinotecan (#2); gemcitabine/abraxane (#3); 5FU/liposomal irinotecan (#4); alomfilimab (ICOS-targeted antibody)/atezolizumab (#5); MVT-5873 (anti-CA 19-9 antibody) (#6). Dosing: ERAS-007 125 mg BID-QW",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bb996fc-1073-4738-b707-d86ce6000d86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "HERKULES-1 Case Study: Single agent ERAS-007 response 70-year-old female with KRAS G12V metastatic pancreatic cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15e982d1-db15-4e28-bf54-6049c3a2c3c8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "d60483e4-36a6-4856-b644-c207a353bcaa",
      "evidence": "Baseline vs 16 Weeks CT scans",
      "confidence": 0.8
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a5eec7eb-0df2-4ebd-a54f-0cc757b4b9ff",
      "evidence": "31% reduction in tumor size",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}